Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.92 |
| ▸ | AR | P10275 | 3/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.69 |
| ▸ | CCL2 | P13500 | 2/20 | 0.53 |
| ▸ | TAF1 | P21675 | 1/20 | 0.53 |
| ▸ | BRD2 | P25440 | 1/20 | 0.53 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.53 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.53 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL747417 | 0.96 | BRD4 (1.00) | BRD4ARKCNH2CCL2TAF1 | |
| SCHEMBL749387 | 0.92 | BRD4 (0.78) | BRD4ARKCNH2CCL2TAF1 | |
| SCHEMBL3471861 | 0.91 | BRD4 (0.77) | BRD4ARKCNH2CCL2TAF1 | |
| SCHEMBL747324 | 0.91 | BRD4 (0.79) | BRD4ARKCNH2CCL2TAF1 | |
| SCHEMBL748503 | 0.90 | BRD4 (0.78) | BRD4ARKCNH2CCL2TAF1 | |
| SCHEMBL753860 | 0.89 | BRD4 (0.87) | BRD4ARKCNH2CCL2TAF1 | |
| SCHEMBL3476264 | 0.88 | BRD4 (0.75) | BRD4ARKCNH2CCL2TAF1 | |
| SCHEMBL747296 | 0.88 | BRD4 (0.73) | BRD4ARKCNH2CCL2TAF1 | |
| SCHEMBL748719 | 0.88 | BRD4 (0.84) | BRD4ARKCNH2CCL2TAF1 | |
| SCHEMBL746952 | 0.87 | BRD4 (0.84) | BRD4ARKCNH2CCL2TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430024-A1 | [1,2,4]TRIAZOLO [4,3-B]PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | AstraZeneca AB (SE) | 2012-03-21 | — | — | EP | claimed |
| WO-2010131022-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | claimed |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | claimed |
| EP-2430024-A1 | [1,2,4]TRIAZOLO [4,3-B]PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | AstraZeneca AB (SE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010131022-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | AR, NR5A1, KLK3 | BRD4 635/4885AR 1/4885KCNH2 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.